Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody.
about
UstekinumabDefining the functional states of Th17 cellsRole of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosisNeuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Emerging therapies in multiple sclerosis.Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitisEffects of early IL-17A neutralization on disease induction in a primate model of experimental autoimmune encephalomyelitis.Kainic Acid-induced neurotoxicity: targeting glial responses and glia-derived cytokines.Cytokine-based immunointervention in the treatment of autoimmune diseases.Gene therapy in nonhuman primate models of human autoimmune disease.IL12Rβ1: the cytokine receptor that we used to know.Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates.Advantages and Risks of Husbandry and Housing Changes to Improve Animal Wellbeing in a Breeding Colony of Common Marmosets (Callithrix jacchus).Discrepant effects of human interferon-gamma on clinical and immunological disease parameters in a novel marmoset model for multiple sclerosis.Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvantDysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients.A novel human truncated IL12rβ1-Fc fusion protein ameliorates experimental autoimmune encephalomyelitis via specific binding of p40 to inhibit Th1 and Th17 cell differentiation.IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.Novel therapeutic modalities to address nondrugable protein interaction targets.Ustekinumab in the therapy of chronic plaque psoriasis.An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates.Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus).Ustekinumab: a new option in psoriasis therapy.Pathogenic CD8(+) T cells in multiple sclerosis.Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development.Monoclonal antibodies as disease modifying therapy in multiple sclerosis.Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.The use of ustekinumab in autoimmune disease.Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS.Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.The evidence for a role of B cells in multiple sclerosis.Monoclonal antibodies in neuroinflammatory diseases.Th17 cells in immunity and autoimmunity.Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.The primate autoimmune encephalomyelitis model; a bridge between mouse and man.An essential role of virus-infected B cells in the marmoset experimental autoimmune encephalomyelitis model.Experimental Models of Autoimmune Demyelinating Diseases in Nonhuman Primates.A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model.
P2860
Q24651927-4A09EA55-A7F2-48A6-A638-BF849C9A6A9FQ26998296-135DD8E0-F006-44FC-AABE-A37BF253A3BAQ28082878-971F8039-3678-4E17-96FE-B8092B053E3FQ30699740-31804439-806C-4F0B-B85E-D46EEA91C058Q31015100-3563F7F6-DC8E-45E9-B50F-466C7E3AB8D8Q34575334-E3233104-085F-48DA-A5F0-A07ADC25D746Q35082644-7F0A9F6E-DC04-4922-AA80-5A4960AA3D7AQ35092168-7578AF73-62C9-4BDF-9E82-35B1649391EDQ35109131-01920291-3E00-4BAC-A36A-368B8DC169F0Q35122173-1D818192-22EE-4014-9B6C-DCC548563EACQ35136546-FC1F343B-DD25-4345-9126-E635FB70AC47Q35607368-799EC6F2-A8D5-4285-86FB-4264427AF19BQ35702194-6BA97A1A-F59D-44DE-BA7D-2B2453EB9B6DQ35759597-A119C506-2688-4C59-B959-592C8D209A35Q36071018-AE29F13F-DEAA-4F3A-9F3F-3DDDCBCBE905Q36213007-B9A1E31C-CF6B-4D8E-BD75-52AF23B7CE58Q36557095-6A2CE7F4-7A7A-4689-BAD1-F337D7B70F29Q36825016-F1CCD31A-0DC1-42B2-BCE4-95699F1DCB06Q37019872-F110031B-B3D5-4DCF-A3EE-4B5F8C49AF4EQ37255013-B85CFB49-022B-484F-84CD-8E3D148817A1Q37303190-644F6E18-5D76-4EBE-A100-0332CA52614DQ37397401-FD8E296E-B7E7-4E86-8723-940E2C1692D5Q37428522-01E75B3B-4C0D-44D3-AFFF-6F40E4BBF3DEQ37523846-F273A09A-C439-43C6-BEEC-8F51880044EBQ37594690-0F057CBF-4A0C-4743-AD95-D309FA7A18BEQ37614318-0F8243B3-CE6B-41D9-9DB7-1810359D602CQ37668086-75A7AC4A-60BA-44BE-8A5B-2C2D0401EE7CQ37675050-817AFB8D-3DB8-48AB-A47D-74F8CDCBA378Q37706606-92CC6A77-B4CF-4CE2-8683-C4F29A39E26FQ37735773-08D2563C-964A-4A1B-89F0-F7D3AE557743Q37771933-2E9AF55D-944C-4EFC-9918-2C6419E35044Q37968620-F096DF2C-A8C4-4FC0-A073-C1D2B1005126Q37993033-BC970B04-985F-4989-9B0C-BB0DB340FC63Q38092121-74AB0125-094F-4F71-B873-766C21924356Q38181087-F8F2AB8F-2A9E-498C-BFC1-78E89AC4C426Q38286209-C92ED007-B8AC-41C5-8A3B-5F7343741D21Q38497590-B2811995-045C-42C7-99F4-56D86446091BQ38728578-28AFEF42-05E1-426D-8169-4FF38AB20159Q39352482-75ECA7C9-7D50-4876-AA48-1818976B4069Q39458392-76119C3E-EA0A-44CB-82B6-434BCCC4E2A0
P2860
Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Prevention of experimental aut ...... -IL-12p40 monoclonal antibody.
@en
Prevention of experimental aut ...... -IL-12p40 monoclonal antibody.
@nl
type
label
Prevention of experimental aut ...... -IL-12p40 monoclonal antibody.
@en
Prevention of experimental aut ...... -IL-12p40 monoclonal antibody.
@nl
prefLabel
Prevention of experimental aut ...... -IL-12p40 monoclonal antibody.
@en
Prevention of experimental aut ...... -IL-12p40 monoclonal antibody.
@nl
P2093
P1476
Prevention of experimental aut ...... -IL-12p40 monoclonal antibody.
@en
P2093
Allen Schantz
Bert A 't Hart
David Peritt
George Treacy
Herbert P M Brok
Jon D Laman
Marjan van Meurs
P304
P356
10.4049/JIMMUNOL.169.11.6554
P407
P50
P577
2002-12-01T00:00:00Z